Gut bacteria capsule could slow fatty liver disease
NCT ID NCT07488975
First seen Apr 09, 2026 · Last updated May 10, 2026 · Updated 7 times
Summary
This early-stage study tests a pasteurized probiotic (pAKK_LWHK0003) in 40 adults with metabolic fatty liver disease (MASLD). The goal is to see if the capsule safely reduces liver fat and scarring over 12 to 16 weeks. Participants take different doses or a placebo. The approach targets the gut-liver connection to manage the disease, not cure it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Taiwan University Hospital
RECRUITINGTaipei, Taiwan
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.